Werewolf Therapeutics, Inc. Stock Price, News & Analysis

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced its participation in the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. CEO Daniel J. Hicklin, Ph.D., will present an overview of the company on-demand starting January 10 at 7 a.m. EST. Werewolf is focused on developing conditionally activated therapeutics that enhance the immune system for cancer treatment, utilizing its proprietary PREDATOR™ platform. The company's lead candidates, WTX-124 and WTX-330, target tumor microenvironments while minimizing peripheral activation.

Werewolf Therapeutics (Nasdaq: HOWL) announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. The NBI measures the performance of biotechnology and pharmaceutical securities on the Nasdaq Stock Market. Companies in the index must meet strict eligibility criteria, enhancing Werewolf's visibility in the market. Werewolf focuses on conditionally activated therapeutics to boost the immune response against cancer, leveraging its PREDATOR™ platform and developing INDUKINE™ molecules, including WTX-124 and WTX-330, for solid tumor treatment.

Werewolf Therapeutics (Nasdaq: HOWL) announced promising preclinical data on its INDUKINE molecules, IL-12 and IFNα, which inhibited lymphoma tumor growth in mice and showed tolerability in non-human primates. These results will be presented at the 63rd American Society of Hematology Annual Meeting on December 12, 2021. The studies suggest that these therapeutics may represent a breakthrough in cancer treatment by enhancing anti-tumor immune responses while reducing adverse effects associated with traditional cytokines.

Werewolf Therapeutics (Nasdaq: HOWL) reported significant advancements in their clinical pipeline, highlighting a collaboration with Merck to assess WTX-124 combined with KEYTRUDA. The company plans to file INDs for WTX-124 and WTX-330 in H1 2022. As of September 30, 2021, cash reserves totaled $170.4 million, a notable increase from $92.6 million at the end of 2020. However, net losses for Q3 2021 were $13.8 million, up from $6.1 million year-over-year. Overall, Werewolf's solid financial position supports its ongoing R&D efforts.

Werewolf Therapeutics (Nasdaq: HOWL), a pioneering biopharmaceutical company, has announced management will present at two key investor conferences this month. The Jefferies Global Healthcare Conference is scheduled for November 18th at 3:00 AM EST, followed by the Evercore ISI HealthCONx Conference on November 30th at 10:30 AM EST. The webcasts will be available on their investor relations webpage. The company aims to advance its innovative INDUKINE™ therapeutics, designed to activate the immune system against cancer, particularly through products WTX-124 and WTX-330.

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the appointment of Meeta Chatterjee, Ph.D., as a new board member. Dr. Chatterjee brings over 30 years of experience in pharmaceutical R&D and business development, previously serving at Legend Biotech Corporation and Merck Research Labs. She aims to enhance the company's strategy as it advances its lead product candidates, WTX-124 and WTX-330, targeting solid tumors. This strategic addition is anticipated to strengthen the board's capabilities during a pivotal time for the company's development.

Werewolf Therapeutics (Nasdaq: HOWL) announced the presentation of promising preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place from November 10-14, 2021. This data showcases the potential of their INDUKINE™ molecules, specifically WTX-124 and WTX-330, in enhancing anti-tumor immune responses. The results will be included in IND applications expected to be filed in the first half of 2022. The abstracts will be available on the SITC website starting November 9, 2021.

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) will present at the Next-Gen Cytokine Therapeutics Summit on September 22, 2021. Chief Scientific Officer, Cynthia Seidel-Dugan, Ph.D., will discuss advancements in cytokine therapeutics at 4:20 PM EDT, followed by Chief Medical Officer, Randi Isaacs, M.D., on a panel discussing the future of cytokine therapies at 4:50 PM EDT. The company focuses on innovative therapeutics that leverage its proprietary PREDATOR™ platform to enhance cancer treatment through conditionally activated INDUKINE™ molecules.

Werewolf Therapeutics, Inc. (Nasdaq: HOWL), based in Cambridge, Massachusetts, will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021. CEO Daniel J. Hicklin, Ph.D. will provide a company overview available on-demand starting September 13 at 7:00 am EDT, archived for 90 days. Werewolf specializes in developing conditionally activated therapeutics to enhance the immune system's response to cancer, leveraging its innovative PREDATOR™ platform and its lead candidates, WTX-124 and WTX-330, for solid tumors.